Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 1
1985 5
1986 1
1987 12
1988 12
1989 19
1990 21
1991 22
1992 24
1993 46
1994 64
1995 68
1996 95
1997 95
1998 111
1999 109
2000 118
2001 130
2002 149
2003 164
2004 220
2005 219
2006 213
2007 295
2008 396
2009 502
2010 605
2011 782
2012 929
2013 1078
2014 1347
2015 1441
2016 1590
2017 1789
2018 2013
2019 2277
2020 2695
2021 3270
2022 3358
2023 3512
2024 4908
2025 5702
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35,893 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide for fertility-sparing treatment in obese/overweight patients with endometrial cancer and atypical hyperplasia: a phase II single-arm clinical trial protocol.
Zheng J, Yang J, Yang J. Zheng J, et al. BMJ Open. 2025 Nov 5;15(11):e105429. doi: 10.1136/bmjopen-2025-105429. BMJ Open. 2025. PMID: 41198197
Tirzepatide is currently the most effective glucagon-like peptide-1 receptor agonist for weight control. This trial aims to explore the synergistic effects and safety of tirzepatide combined with standard fertility-preserving treatment for endom …
Tirzepatide is currently the most effective glucagon-like peptide-1 receptor agonist for weight control. …
The Obesity Paradox in Heart Failure With Preserved Ejection Fraction: Untangling Body Composition, Inflammation, and Outcomes.
Tannous L, Tated R, Ramesh J, Joshi DK, Jain H, Agrawal SP. Tannous L, et al. Cardiol Rev. 2025 Nov 3. doi: 10.1097/CRD.0000000000001106. Online ahead of print. Cardiol Rev. 2025. PMID: 41198097
Critics highlight confounding from cachexia-related weight loss, lead-time bias, and BMI's inability to distinguish fat from muscle. Emerging therapies, including glucagon-like peptide-1 receptor agonists and structured exercise regimens, demons …
Critics highlight confounding from cachexia-related weight loss, lead-time bias, and BMI's inability to distinguish fat from muscle. Emergin …
Revisiting the metabolic crosstalk between type 2 diabetes and hyperuricemia: Pathophysiological insights and therapeutic perspectives.
Xia X, Niu H, Xu C, Liu X, Zhang G, Ling J. Xia X, et al. Biochim Biophys Acta Mol Basis Dis. 2025 Nov 4:168102. doi: 10.1016/j.bbadis.2025.168102. Online ahead of print. Biochim Biophys Acta Mol Basis Dis. 2025. PMID: 41197817 Review.
We highlight the therapeutic implications of glucose-lowering agents with urate-modulating properties, such as SGLT2 inhibitors and metformin, and assess the dual metabolic effects of uric acid-lowering agents. ...
We highlight the therapeutic implications of glucose-lowering agents with urate-modulating properties, such as SGLT2 inhibitors and m …
Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Neovascular Age-Related Macular Degeneration in a National Cohort Study.
Allan KC, Cohn EF, Bala S, Kim SB, Kaelber DC, Singh RP, Talcott KE, Mammo DA, Rachitskaya AV. Allan KC, et al. Ophthalmol Retina. 2025 Nov 4:S2468-6530(25)00504-4. doi: 10.1016/j.oret.2025.10.020. Online ahead of print. Ophthalmol Retina. 2025. PMID: 41197713
PURPOSE: To investigate the risk of neovascular age-related macular degeneration (AMD) in patients taking glucagon-like peptide-1 receptor agonists (GLP-1RAs). DESIGN: Retrospective cohort study. ...
PURPOSE: To investigate the risk of neovascular age-related macular degeneration (AMD) in patients taking glucagon-like pep …
SGLT2 inhibitors versus DPP-4 inhibitors and dementia risk in type 2 diabetes: A meta-analysis of cohort studies.
Zhong Z, Zhao S, He W, Li R, Xia S. Zhong Z, et al. Arch Gerontol Geriatr. 2025 Oct 28;141:106065. doi: 10.1016/j.archger.2025.106065. Online ahead of print. Arch Gerontol Geriatr. 2025. PMID: 41197554
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown neuroprotective potential. This meta-analysis aimed to compare the effects of SGLT2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors on dementia risk in patients with type 2 diabetes me …
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown neuroprotective potential. This meta-analysis aimed to compa …
Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes.
Nakatani E, Ohno H, Nagahama T, Tonoike T, Yui H, Satoh T, Matsunaga T, Funaki D, Ueki C, Ohata E, Miyakoshi A, Igarashi A, Tanaka Y, Kaneda H, Kumamaru H, Sugawara A. Nakatani E, et al. PLoS One. 2025 Nov 6;20(11):e0336038. doi: 10.1371/journal.pone.0336038. eCollection 2025. PLoS One. 2025. PMID: 41196845
Patients initiating treatment with either a biguanide or an SGLT2 inhibitor, while avoiding the alternative class during the first 12 months but allowing other glucose-lowering agents, were included. ...Median daily drug cost was 124.7 JPY for biguanides and 184.0 JPY for …
Patients initiating treatment with either a biguanide or an SGLT2 inhibitor, while avoiding the alternative class during the first 12 …
Pathomechanisms, genetic insights and therapeutics in diabetes-associated dementia.
Meher R, Sahu R, Ranjit SK, Swain TR, Acharya B, Feehan J, Sahu PK, Apostolopoulos V. Meher R, et al. J Endocrinol. 2025 Nov 6:JOE-25-0016. doi: 10.1530/JOE-25-0016. Online ahead of print. J Endocrinol. 2025. PMID: 41196686
Promising therapies, including GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and anti-inflammatory drugs, are reviewed alongside emerging approaches such as gene therapy, stem cell therapy, and immunomodulation. ...
Promising therapies, including GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and anti-inflammatory drugs, are reviewed …
35,893 results
You have reached the last available page of results. Please see the User Guide for more information.